Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
15.65
-0.10 (-0.63%)
Market open: Aug 12, 2026, 10:13 AM EDT
15.75
0.00 (0.00%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells products for the treatment of cardiovascular disease and cancer diagnoses in the United States and internationally. The company operates through Med Tech and Med Device segments. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company’s thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers’ off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage. It also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which include angiographic catheters, guidewires, drainage catheters, and micropuncture kits for use in invasive procedures. In addition, the company provides total abscession drainage catheters for multi-purpose/general and biliary configurations, and nephrostomy options; mini stick MAX Coaxial microintroducer kits and micro-introducer kits; ports; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero Microwave Tissue Ablation System includes solero microwave generator and the solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.
| Name | Position |
|---|---|
| Mr. Benjamin H. Davis | Senior Vice President of Business Development & Strategy |
| Mr. Chad T. Campbell | Senior VP and GM of Oncology & Interventional Devices |
| Mr. James C. Clemmer | CEO, President & Director |
| Mr. Lawrence T. Weiss | Senior VP, Chief Legal Officer & Corporate Secretary |
| Mr. Saleem M. Cheeks | Vice President of Communications |
| Mr. Stephen A. Trowbridge | Executive VP & CFO |
| Mr. Warren G. Nighan | Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain |
| Ms. Kim L. Seabury | Senior Vice President of Information Technology |
| Ms. Laura Piccinini | Senior VP and GM of Cardiovascular & International |
| Ms. Marna I. Bronfen-Moore | Senior Vice President of Human Resources |
| Date | Type | Document |
|---|---|---|
| 2026-07-14 | 10-K | ango-20260531.htm |
| 2026-04-23 | 8-K | ef20071331_8k.htm |
| 2026-04-02 | 8-K | ef20069681_8k.htm |
| 2026-04-02 | 10-Q | ango-20260228.htm |
| 2026-02-03 | 8-K | ef20064537_8k.htm |
| 2026-01-14 | 8-K | ef20062701_8k.htm |
| 2026-01-06 | 8-K | ef20062354_8k.htm |
| 2026-01-06 | 10-Q | ango-20251130.htm |
| 2025-11-12 | 8-K | ef20058726_8k.htm |
| 2025-10-21 | S-8 | ef20057449_s8.htm |